Minerva Surgical Inc UTRS
We take great care to ensure that the data presented and summarized in this overview for MINERVA SURGICAL INC is accurate and up-to-date, based on a comprehensive analysis of 13F filing forms for institutional ownership and form 4 filings for insider transactions. Please note that this data may differ from other sources and should not be relied upon as the sole basis for investment decisions.
Latest Institutional Activity in UTRS
Top Purchases
Top Sells
About UTRS
Minerva Surgical, Inc., a commercial-stage medical technology company, develops, manufactures, and commercializes minimally invasive solutions to meet the uterine healthcare needs of women in the United States. The company offers Minerva ES Endometrial Ablation System and Genesys HTA Endometrial Ablation System, which are endometrial ablation devices; Symphion Tissue Removal System, a minimally invasive uterine tissue removal system to combine bladeless tissue resection and coagulation, continuous visualization, and intrauterine pressure monitoring; and Resectr Tissue Resection Device, a handheld surgical instrument to enable the hysteroscopic removal and diagnosis of endometrial polyps. Its devices are utilized by obstetrician-gynecologists in various medical treatment settings, including hospitals, ambulatory surgical centers, and physician offices. The company was incorporated in 2008 and is headquartered in Santa Clara, California.
Insider Transactions at UTRS
Insider Transaction List
View all| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 09
2023
|
New Enterprise Associates 13 LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
24,437,927
+41.51%
|
$0
$0.2 P/Share
|
|
Jul 19
2022
|
Derrick Sung Director |
BUY
Grant, award, or other acquisition
|
Direct |
86,956
+50.0%
|
$173,912
$2.3 P/Share
|
|
Jun 10
2022
|
Jill Anderson Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,792
+50.0%
|
$99,584
$2.41 P/Share
|
|
Jun 10
2022
|
Catherine Coste Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,792
+27.76%
|
$99,584
$2.41 P/Share
|
|
Jun 10
2022
|
Niquette L. Hunt Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,792
+50.0%
|
$99,584
$2.41 P/Share
|
|
Jun 10
2022
|
David Renzi Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,792
+50.0%
|
$99,584
$2.41 P/Share
|
|
Jun 10
2022
|
Ross A Md Jaffe Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,792
+50.0%
|
$99,584
$2.41 P/Share
|
|
Jun 10
2022
|
Ali Behbahani Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,792
+46.07%
|
$99,584
$2.41 P/Share
|
|
May 02
2022
|
David M Clapper President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
229,732
+41.55%
|
-
|
|
May 02
2022
|
Joel R Jung CFO |
BUY
Grant, award, or other acquisition
|
Direct |
60,198
+21.43%
|
-
|
|
May 02
2022
|
Dominique J. Filloux COO |
BUY
Grant, award, or other acquisition
|
Direct |
60,198
+18.44%
|
-
|
|
May 02
2022
|
Evgueni V. Skalnyi VP Medical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
49,755
+16.9%
|
-
|
|
Dec 15
2021
|
David M Clapper President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
93,500
+50.0%
|
-
|
|
Dec 15
2021
|
Dominique J. Filloux COO |
BUY
Grant, award, or other acquisition
|
Direct |
24,500
+10.62%
|
-
|
|
Dec 15
2021
|
Joel R Jung CFO |
BUY
Grant, award, or other acquisition
|
Direct |
24,500
+13.24%
|
-
|
|
Dec 15
2021
|
Evgueni V. Skalnyi VP Medical Affairs |
BUY
Grant, award, or other acquisition
|
Direct |
20,250
+9.41%
|
-
|
|
Dec 13
2021
|
David M Clapper President and CEO |
BUY
Open market or private purchase
|
Indirect |
25,000
+3.74%
|
$100,000
$4.94 P/Share
|
|
Oct 26
2021
|
Ross A Md Jaffe Director |
BUY
Conversion of derivative security
|
Indirect |
94,755
+50.0%
|
-
|
|
Oct 26
2021
|
New Enterprise Associates 13 LP > 10% Shareholder |
BUY
Open market or private purchase
|
Direct |
1,300,000
+11.51%
|
$15,600,000
$12.0 P/Share
|
|
Oct 26
2021
|
New Enterprise Associates 13 LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
8,699,125
+39.58%
|
-
|